本文關(guān)鍵詞： 晚期腎癌 阿昔替尼 索拉非尼 一線治療 療效　出處：《中國(guó)腫瘤生物治療雜志》2017年09期 　論文類型：期刊論文

【摘要】：目的:比較阿昔替尼與索拉非尼一線治療晚期腎癌的臨床療效,探討分子靶向藥物阿昔替尼能否作為一線治療晚期腎癌的優(yōu)選藥物。方法:選取�？谑腥嗣襻t(yī)院腫瘤科60例晚期腎癌患者,以數(shù)字表法隨機(jī)分為試驗(yàn)組和對(duì)照組,每組30例。實(shí)驗(yàn)組給予阿昔替尼,對(duì)照組給予索拉非尼治療,比較兩組患者的DCR、ORR、PFS、OS及不良反應(yīng)的差異。結(jié)果:兩組患者均能完成試驗(yàn)并進(jìn)行結(jié)果評(píng)價(jià)。試驗(yàn)組和對(duì)照組的DCR分別為83.33%和80.00%、ORR分別為20.00%和20.00%,差異均無統(tǒng)計(jì)學(xué)意義(P0.05);試驗(yàn)組和對(duì)照組的中位PFS分別為12.8個(gè)月和10.1個(gè)月,差異有統(tǒng)計(jì)學(xué)意義(P0.05);中位OS分別為22.2個(gè)月和22.8個(gè)月,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者不良反應(yīng)發(fā)生率相近,差異無統(tǒng)計(jì)學(xué)意義(P0.05),主要表現(xiàn)在高血壓、全身反應(yīng)、手足皮膚綜合征、消化道反應(yīng)、肝功能損害,未見嚴(yán)重不良反應(yīng)。結(jié)論:分子靶向藥物阿昔替尼較索拉非尼一線治療晚期腎癌更能延長(zhǎng)患者中位PFS,兩藥治療后患者的DCR、ORR、OS及不良反應(yīng)相似,阿昔替尼可以作為一線治療晚期腎癌的優(yōu)選。
[Abstract]:Objective: to compare the clinical efficacy of acicitinib and sorafenib in the treatment of advanced renal cell carcinoma. Methods: 60 patients with advanced renal cell carcinoma in Department of Oncology, Haikou people's Hospital, were randomly divided into trial group and control group by digital table method. Each group (30 cases) was treated with acicatinib in the experimental group and Solafenib in the control group. Results: two groups of patients were able to complete the test and evaluate the results. The DCR of the test group and the control group were 83.33% and 80.005, respectively. There was no significant difference between the two groups (P 0.05). The median PFS of the test group and the control group were 12. 8 months and 10. 1 months, respectively. The difference was statistically significant (P 0.05), and the median OS was 22.2 months and 22.8 months, respectively. There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). The main manifestations were hypertension, systemic reaction, and skin syndrome of the hand and foot. Conclusion: the molecular targeted drug oxetinib can prolong the median PFS in patients with advanced renal cell carcinoma, and the DCR-ORROS and adverse reactions of the patients after the treatment are similar, conclusion: the molecular targeted drug oxetinib can prolong the median PFS in patients with advanced renal cell carcinoma. Acetinib can be used as a first-line treatment for advanced renal cell carcinoma.
【作者單位】： �？谑腥嗣襻t(yī)院中醫(yī)科;
【分類號(hào)】：R737.11

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉金華,劉金梅,陳云;五大連池天然礦泉水治療晚期腎癌一例報(bào)告[J];中國(guó)療養(yǎng)醫(yī)學(xué);2001年05期

2 楊伯平;;晚期腎癌的綜合治療[J];山東醫(yī)藥;2006年21期

3 許公普;仝用;;中晚期腎癌介入治療的臨床應(yīng)用價(jià)值[J];中國(guó)社區(qū)醫(yī)師(醫(yī)學(xué)專業(yè));2010年23期

4 徐光煒;馬曉兵;鹿?fàn)栍?xùn);王慧英;劉燕平;;綜合治療晚期腎癌多發(fā)遠(yuǎn)處轉(zhuǎn)移一例[J];海軍醫(yī)學(xué);1996年04期

5 徐光煒,馬曉兵,鹿?fàn)栺Z,王慧英,劉燕平;綜合治療晚期腎癌多發(fā)遠(yuǎn)處轉(zhuǎn)移1例[J];人民軍醫(yī);1997年09期

6 徐光煒,馬曉兵,鹿?fàn)栍?xùn),王慧英,劉燕平;綜合治療晚期腎癌多發(fā)遠(yuǎn)處轉(zhuǎn)移1例[J];腫瘤防治研究;1997年04期

7 徐光煒,馬曉兵,鹿?fàn)栺Z,王慧英,劉燕平;綜合治療晚期腎癌多處轉(zhuǎn)移1例[J];中級(jí)醫(yī)刊;1998年02期

8 馬建輝;;晚期腎癌治療的重大突破[J];抗癌之窗;2009年02期

9 張犁,劉軍生,董沛生;晚期腎癌的生物治療[J];南京軍醫(yī)學(xué)院學(xué)報(bào);2000年04期

10 宋希雙,何中舟,殷積斌,張仁科,車翔宇,王建伯;中、晚期腎癌的介入、手術(shù)和生物聯(lián)合治療[J];中華外科雜志;2004年23期

相關(guān)會(huì)議論文 前10條

1 郭軍;;如何選擇晚期腎癌治療的靶向藥物?[A];第三屆中國(guó)腫瘤內(nèi)科大會(huì)教育集暨論文集[C];2009年

2 居小兵;張煒;張煒小;殷長(zhǎng)軍;徐正銓;;索拉非尼治療治療晚期腎癌的療效觀察[A];第十五屆全國(guó)泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年

3 郭新會(huì);楊培金;陳錫俊;劉世超;高秀蘭;;中晚期腎癌姑息性介入治療的臨床應(yīng)用價(jià)值[A];第二屆全國(guó)非血管性與血管性介入新技術(shù)學(xué)術(shù)研討會(huì)暨第三屆介入放射學(xué)新技術(shù)提高班論文匯編[C];2005年

4 張正望;錢偉慶;孫忠全;丁海雍;宋建達(dá);;索拉非尼(多吉美)治療晚期腎癌的有效性和安全性初探(附3例報(bào)告)[A];第十五屆全國(guó)泌尿外科學(xué)術(shù)會(huì)議論文集[C];2008年

5 趙菊平;沈周俊;謝欣;何z殉，

本文編號(hào)：1522745